2,864 Results

Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin.

Objectives: To characterize the expression of the IL‐17 isoforms and receptors in lesional and nonlesional psoriatic skin.

Economic and Comorbidity Burden Among Patients with Moderate-to-Severe Psoriasis.

Objective: To compare the prevalence of comorbidities, health care resource utilization, and costs between moderate-to-severe PsO patients and demographically matched controls.

Brodalumab: an evidence-based review of its potential in the treatment of moderate-to-severe psoriasis.

Advances in knowledge regarding the pathogenesis of psoriasis have allowed the development of a new class of agents known as biologic drugs. Data confirm that T helper (Th)17 and interleukin (IL)-17 signaling has a crucial role...

Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003-2011.

Objective: To ascertain impairment in quality of life and work productivity among patients with psoriasis and psoriatic arthritis.

Infliximab in inflammatory bowel disease.

Anti-tumor necrosis factor (TNF) therapy has revolutionized the medical treatment of the inflammatory bowel diseases (IBD), Crohn’s disease (CD), and ulcerative colitis. Twenty years ago, infliximab became the first anti-TNF...

Natalizumab for induction of remission in Crohn's disease.

Background: This systematic review update summarizes the current evidence on the use of natalizumab for induction of remission in Crohn's disease (CD).

Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD).

Objectives: To assess the efficacy and safety of combined aclidinium bromide and long-acting beta2-agonists in stable COPD.

Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial.

Background: There is a direct relationship between bodyweight and risk of diabetes. Lorcaserin, a selective serotonin 2C receptor agonist that suppresses appetite, has been shown to facilitate sustained weight loss in obese or...

Treating obesity in patients with cardiovascular disease: the pharmacotherapeutic options.

Areas covered: Herein, the authors review the most commonly used FDA approved medications for the treatment of obesity, describing their mechanism of action, and the efficacy and safety of the medications as seen in...

Interaction of obesity and atrial fibrillation: an overview of pathophysiology and clinical management.

Areas covered: We will briefly discuss the obesity paradox and its mechanisms regarding cardiac and hemodynamic function changes. In the first main part of this review, we will be discussing risk assessment studies...

Load more